Haematology

Pernicious anaemia: recognition, diagnosis and management

How to spot the signs and symptoms of pernicious anaemia, the difficulties in gaining an accurate diagnosis and the importance of individualised, long-term management for patients.…

Community pharmacies in England carry out more than 110,000 blood pressure checks in six months

Community pharmacies also provided ambulatory blood pressure monitoring to nearly 5,000 patients.…

Whole-genome sequencing is ‘feasible’ for screening in primary care, research suggests

Presenting their findings, study authors said genomic sequencing in primary care could change the way patients and their families are managed by GPs.…

Working as a pharmacist on the groundbreaking new CAR-T therapy

Clinical pharmacist Jackie Chappell shares her experiences of working with CAR-T therapy, a new cell-engineering treatment for cancer.…

Pharmacy teams may not spot sepsis under new consultation scheme, warns pharmacy negotiator

There is a “significant risk” that pharmacy teams will fail to spot sepsis in patients presenting under the new community pharmacist consultation scheme due to begin at the end of October 2019, a pharmacy negotiator has said.…

NHS England to fund ‘life-changing’ haemophilia drug

NHS England is to fund a treatment for severe haemophilia that will “dramatically” cut risk of life-treatening bleeds for thousands of patients.…

Multiple myeloma: an expensive revolution

New treatments for this rare form of cancer have transformed patient survival rates, but the benefits have come with huge costs.…

Multiple myeloma: pharmacological management

Although multiple myeloma is currently regarded as being incurable in the majority of patients, the outlook for patients diagnosed with the condition has improved markedly over the past 40 years, with survival rates quadrupling. Significant advances in both treatment and supporti…

Biosimilar anticancers get support from British oncology pharmacists

The British Oncology Pharmacy Association (BOPA), a charity of cancer specialist pharmacists, has backed the use of biosimilar monoclonal antibodies (MABs) as part of cancer treatment. In a statement, published on 5 February 2017 in an attempt to clarify where these new products fit into …

How to identify causes of a subtherapeutic INR

Pharmacists and healthcare professionals are often involved in the management of patients with subtherapeutic international normalised ratios (INRs), the cause of which is important to identify because this will affect decisions and the subsequent management of the patient.…